Decision aids and prostate cancer: how useful are they?

Your sitemaster has long had concerns about the real value of decision aids in helping men to think about and come to conclusions about controversial issues in the diagnosis and management of prostate cancer. … READ MORE …

AS in practice in a specific US community setting

In a presentation at the ASCO annual meeting, Dr. Ronald Chen reported that just 32 percent of newly diagnosed men who were initially managed on active surveillance (AS) in North Carolina between 2011 and 2013 were actually managed in compliance with guideline recommended monitoring. … READ MORE …

BPH, 5-ARIs, PSA, and risk for prostate cancer diagnosis

It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …

Ploidy status and risk for prostate cancer-specific mortality

We have known for many years (certainly at least 20) that the presence of abnormal numbers of chromosomes (aneuploidy) in prostate cancer tumor cells is a risk factor for more serious forms of prostate cancer. … READ MORE …

No association between alcohol consumption and lethal prostate cancer

A newly published article in the Journal of Clinical Oncology has again confirmed that there seems to be no really meaningful association between moderate alcohol consumption and risk for lethal prostate cancer. … READ MORE …

Depression in men on ADT

Depression is relatively common among men with prostate cancer. Indeed, it may be a lot more common than we can currently document. … READ MORE …

No mortality benefit from dietary supplements … says Harvard and Tufts

The issue of whether routine use of dietary supplements has any meaningful therapeutic benefit has long been a controversial issue (and we don’t expect that to change as a result of what appears below, but …) … READ MORE …

“To DRE or not to DRE, that is the question”

With apologies to the Bard of Avon and his character Hamlet, the above-misquoted Prince of Denmark, we bring to your attention the most recent article by our good friend Howard Wolinsky on issues related to prostate cancer. … READ MORE …

For those considering treatment with a checkpoint inhibitor

We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …

Low-dose aspirin and prostate cancer-specific mortality

A newly published article — and an associated editorial — in the Annals of Internal Medicine has addressed the possible benefits of taking low-dose aspirin as a method to prevent the progression of newly diagnosed prostate cancer. … READ MORE …

Yes, you are at risk … but risk of exactly what?

An article just published in Urologic Oncology has reported — perhaps not surprisingly — that men who have a single, initial negative biopsy as a consequence of suspicion of prostate cancer are at significant risk for actual diagnosis of prostate cancer over the next 20 years. … READ MORE …

Cardiovascular history, abiraterone acetate, and 6-month mortality rates

In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …

Diet, diagnosis, AS, and the management of lower-risk forms of prostate cancer

Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …

Prognosis of patient progression and outcomes on active surveillance

The prostate cancer research team led by Dr. Peter Pinto at the National Cancer Institute has just published some interesting new information on risk for disease progression in men on active surveillance. … READ MORE …

Chris Haiman is looking for 10,000 black men (with prostate cancer)!

The RESPOND study, which was initiated in July last year, appears to be the largest-ever study of risk factors for prostate cancer among the African American community, and probably among Black men worldwide. … READ MORE …